[go: up one dir, main page]

PE20050687A1 - Antagonistas del receptor hidroisoindolina taquiquinina - Google Patents

Antagonistas del receptor hidroisoindolina taquiquinina

Info

Publication number
PE20050687A1
PE20050687A1 PE2005000090A PE2005000090A PE20050687A1 PE 20050687 A1 PE20050687 A1 PE 20050687A1 PE 2005000090 A PE2005000090 A PE 2005000090A PE 2005000090 A PE2005000090 A PE 2005000090A PE 20050687 A1 PE20050687 A1 PE 20050687A1
Authority
PE
Peru
Prior art keywords
phenyl
tachyquinine
hydroisoindoline
receptor antagonists
etoxy
Prior art date
Application number
PE2005000090A
Other languages
English (en)
Inventor
Jaime Lynn Bunda
Rober J Devita
Sander G Mills
Jinlong Jiang
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PE20050687A1 publication Critical patent/PE20050687A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I DONDE R1 ES H, ALQUILO C1-C6, FENILO, ENTRE OTROS; X ES H, F, METILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (3aS,4S,5R,7aS)-5-{(1S)-1-[3,5-BIS(TRIFLUOROMETILO)FENIL]ETOXI}-4-(4-FLUOROFENIL)-OCTAHIDRO-1H-ISOINDOL; 3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-BIS(TRIFLUOROMETILO)FENIL]ETOXI}-4-(4-FLUOROFENIL)-OCTAHIDRO-2H-ISOINDOL-2-IL]CICLOPENT-2-EN-1-ONA Y (3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-BIS(TRIFLUOROMETILO)FENIL]ETOXI}-4-(4-FLUOROFENIL)-OCTAHIDRO-2H-ISOINDOL-2-IL]-4-HIDROXICICLOPENT-2-EN-1-ONA; ENTRE OTROS. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE LA NEUROQUININA-1 (NK-1) E INHIBIDORES DE LA TAQUIQUININA Y LA SUSTANCIA P Y SON UTILES EN EL TRATAMIENTO DE EMESIS, INCONTINENCIA URINARIA, DEPRESION Y ANSIEDAD
PE2005000090A 2004-01-27 2005-01-24 Antagonistas del receptor hidroisoindolina taquiquinina PE20050687A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53991304P 2004-01-27 2004-01-27
US56122704P 2004-04-09 2004-04-09

Publications (1)

Publication Number Publication Date
PE20050687A1 true PE20050687A1 (es) 2005-09-27

Family

ID=34830494

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000090A PE20050687A1 (es) 2004-01-27 2005-01-24 Antagonistas del receptor hidroisoindolina taquiquinina

Country Status (30)

Country Link
US (3) US7645790B2 (es)
EP (1) EP1711465B1 (es)
JP (1) JP3987100B2 (es)
KR (1) KR20060127927A (es)
AR (1) AR047439A1 (es)
AT (1) ATE382034T1 (es)
AU (1) AU2005207934B2 (es)
BR (1) BRPI0507050A (es)
CA (1) CA2554550C (es)
CO (1) CO5700771A2 (es)
CR (1) CR8522A (es)
CY (1) CY1107167T1 (es)
DE (1) DE602005004011T2 (es)
DK (1) DK1711465T3 (es)
EA (1) EA010598B1 (es)
EC (1) ECSP066716A (es)
ES (1) ES2297687T3 (es)
GE (1) GEP20094691B (es)
HR (1) HRP20080100T3 (es)
IL (1) IL176879A0 (es)
MA (1) MA28359A1 (es)
NI (1) NI200600164A (es)
NO (1) NO339041B1 (es)
NZ (1) NZ548415A (es)
PE (1) PE20050687A1 (es)
PL (1) PL1711465T3 (es)
PT (1) PT1711465E (es)
TW (1) TWI341198B (es)
UA (1) UA84192C2 (es)
WO (1) WO2005073191A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047439A1 (es) 2004-01-27 2006-01-18 Merck & Co Inc Antagonistas del receptor hidroisoindolina taquiquinina
WO2006065711A2 (en) * 2004-12-14 2006-06-22 Merck & Co., Inc. Octahydropyrano[3,4-c]pyrrole tachykinin receptor antagonists
AU2006261930B2 (en) * 2005-06-27 2011-07-14 Merck Sharp & Dohme Corp. Hydroisoindoline tachykinin receptor antagonists
US20100036135A1 (en) * 2005-07-11 2010-02-11 Merck & Co., Inc. Process for Making Hydroisoindoline Tachykinin Receptor Antagonists
WO2007044296A2 (en) * 2005-10-04 2007-04-19 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2007075528A2 (en) * 2005-12-22 2007-07-05 Merck & Co., Inc. Octahydropyrano[3,4-c]pyrrole tachykinin receptor antagonists
EP1978965A2 (en) * 2006-01-24 2008-10-15 Merck & Co., Inc. Hexahydro-3h-pyrrolizin-3-ones useful as tachykinin receptor antagonists
WO2008030389A2 (en) * 2006-09-06 2008-03-13 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
EP2089019A4 (en) * 2006-11-02 2011-05-04 Merck Sharp & Dohme POLYMORPHIC OF A HYDROISOINDOLINE TACHYKININE RECEPTOR ANTAGONIST
WO2008121268A1 (en) * 2007-03-29 2008-10-09 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
WO2008124143A1 (en) * 2007-04-10 2008-10-16 Merck & Co., Inc. Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
NO2729147T3 (es) 2011-07-04 2018-02-03
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
MX366728B (es) * 2013-06-24 2019-07-22 Menlo Therapeutics Inc Uso de serlopitant como antagonistas del receptor nk-1 en prurito.
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
MA49524A (fr) 2017-06-30 2021-05-26 Chase Therapeutics Corp Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
ES2980110T3 (es) 2018-02-26 2024-09-30 Ospedale San Raffaele Srl Antagonistas de NK-1 para uso en el tratamiento del dolor ocular
US20230134843A1 (en) 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency
EP4125875A1 (en) 2020-04-03 2023-02-08 NeRRe Therapeutics Limited An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
WO2021245512A1 (en) 2020-06-02 2021-12-09 Nerre Therapeutics Limited Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650142A (en) * 1995-09-27 1997-07-22 Church & Dwight Co., Inc. Bicarbonate-containing deodorant cosmetic stick compositions
EP0858444A4 (en) 1995-10-18 1999-12-01 Merck & Co Inc Cyclopentyl tachykinin receptor antagonists
CA2540061A1 (en) 2003-09-30 2005-04-14 Merck & Co., Inc. Phenyl pyrrolidine ether tachykinin receptor antagonists
AR047439A1 (es) * 2004-01-27 2006-01-18 Merck & Co Inc Antagonistas del receptor hidroisoindolina taquiquinina

Also Published As

Publication number Publication date
US20050165083A1 (en) 2005-07-28
EA010598B1 (ru) 2008-10-30
CR8522A (es) 2007-06-06
ECSP066716A (es) 2006-10-31
PT1711465E (pt) 2008-02-25
BRPI0507050A (pt) 2007-06-12
CA2554550A1 (en) 2005-08-11
ATE382034T1 (de) 2008-01-15
NI200600164A (es) 2007-05-29
DE602005004011D1 (de) 2008-02-07
EA200601378A1 (ru) 2007-02-27
EP1711465B1 (en) 2007-12-26
GEP20094691B (en) 2009-05-25
UA84192C2 (en) 2008-09-25
MA28359A1 (fr) 2006-12-01
TWI341198B (en) 2011-05-01
NO20063810L (no) 2006-10-26
US7217731B2 (en) 2007-05-15
CY1107167T1 (el) 2012-10-24
US20070161695A1 (en) 2007-07-12
AU2005207934A1 (en) 2005-08-11
CA2554550C (en) 2011-05-03
NZ548415A (en) 2009-11-27
JP2007519728A (ja) 2007-07-19
JP3987100B2 (ja) 2007-10-03
ES2297687T3 (es) 2008-05-01
WO2005073191A1 (en) 2005-08-11
US7645790B2 (en) 2010-01-12
AU2005207934B2 (en) 2010-11-25
PL1711465T3 (pl) 2008-05-30
DE602005004011T2 (de) 2008-12-11
CO5700771A2 (es) 2006-11-30
KR20060127927A (ko) 2006-12-13
NO339041B1 (no) 2016-11-07
EP1711465A1 (en) 2006-10-18
HRP20080100T3 (en) 2008-04-30
DK1711465T3 (da) 2008-03-31
AR047439A1 (es) 2006-01-18
US7345083B2 (en) 2008-03-18
IL176879A0 (en) 2006-10-31
TW200534850A (en) 2005-11-01
US20080280966A1 (en) 2008-11-13
HK1100937A1 (zh) 2007-10-05

Similar Documents

Publication Publication Date Title
PE20050687A1 (es) Antagonistas del receptor hidroisoindolina taquiquinina
PE20050018A1 (es) Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b)
PE20060526A1 (es) Compuestos triciclicos como antagonistas de mglur1
CO5190721A1 (es) Benzazoles: derivados de benzoxazol,y benzotiazol .
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
PE20080827A1 (es) N-(1-hetaril-piperidin-4-il)-(het) arilamidas como moduladores del receptor ep2
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
TW200510441A (en) Novel compounds
CO5611147A2 (es) Derivados de nicotinamida utiles como inhibidores p38
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
PE20010930A1 (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales
PE20110341A1 (es) COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
HRP20100114T1 (hr) Derivati azabiciklo[3.1.0]heksana korisni kao modulatori dopaminskih receptora d3
NO20071258L (no) Imidazolforbindelser.
DK1501507T3 (da) Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet
EA200600348A1 (ru) Новые соединения
PE20090606A1 (es) Nuevos inhibidores de catepsina c y uso
ATE323087T1 (de) Aryl substituierte oxazolidinone mit antibacterieller activität
AR072189A1 (es) Derivados heterociclicos de benzo[b][1,4] oxazinonas moduladores de adrenoreceptores beta 2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de enfermedades del aparato respiratorio.
PE20030610A1 (es) Derivados de 3-azabiciclo[3.1.0]hexano con afinidad a los receptores opioides
PE20070642A1 (es) Compuestos derivados de pirazol como antagonistas del receptor de la progesterona
CO5510023A1 (es) Uso de antagonistas del canal de sodio neuronal para el control de ectoparasitos en animales homeotermicos
PE20100093A1 (es) Derivados de acetileno
ATE478048T1 (de) Pharmazeutisch aktive benzsulfonamidderivate als inhibitoren von protein-jun-kinasen

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed